The pharmacological inhibitors of FABP4 have been shown to be effective in treating various inflammatory diseases, including nonalcoholic steatohepatitis and vascular inflammation in both rodents and pigs (17, 18). This evidence concerns the gene FABP4 and metabolic dysfunction-associated steatohepatitis.